CME Snack

Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer’s Disease

Launch Date
04/01/2024 at 5:00 am EST
Credit Amount
1.0
Credit Expires
04/01/2025
This activity is part of a series

Faculty

Alireza Atri, MD, PhD
Moderator
Chief Medical Officer, Banner Research
Banner Alzheimer’s & Research Institutes Banner Health
Phoenix, Tucson and Sun City, AZ
Director, Banner Sun Health Research Institute
Sun City, AZ
Lecturer on Neurology
Center for Brain/Mind Medicine
Department of Neurology
Brigham and Women’s Hospital, and Harvard Medical School
Boston, MA
Henrik Zetterberg, MD, PhD
Professor of Neurochemistry
Head of the Department of Psychiatry and Neurochemistry
University of Gothenburg
Clinical Chemist, Sahlgrenska University Hospital
Gothenburg, Sweden
Henrik Zetterberg, MD, PhD

Henrik Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a clinical chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a key member of the Hong Kong Center for Neurodegenerative Diseases and Visiting Professor in the University of Wisconsin (UW) Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are in fluid biomarkers for brain diseases, neurodegenerative diseases in particular. He has published more than 2,000 scientific articles and received many awards.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Due to the rising prevalence and significant burden of Alzheimer’s disease there is a critical need for continuing education aimed at bridging existing gaps in clinician knowledge, competence, and performance concerning novel and emerging amyloid-targeting therapies (ATTs), especially in the early symptomatic stages of AD where timely and optimal intervention can significantly alter patient outcomes. By fostering a nuanced understanding of AD neuropathology, biomarker relevance, and the practical application of ATTs, this initiative proposes to equip global dementia specialists, neurologists, geriatricians, and geriatric psychiatrists with the essential knowledge and skills required to improve the diagnostic accuracy and therapeutic management of AD.

In this CMEO Snack entitled, Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer’s Disease, expert faculty will discuss strategies for identifying the neuropathological chances associated with AD, assessing the role of phosphorylated tau biomarkers, evaluating latest data from clinical trials on ATTs, and identifying appropriate patients to ensure timely and optimal management.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the neuropathological changes associated with AD including those occurring downstream of amyloid accumulation, and their relevance to the cognitive and functional decline of early AD
  • Assess the role of phosphorylated tau biomarkers as early indicators of both amyloid and tau accumulation
  • Evaluate the latest data from ATT clinical trials for practical clinical applications
  • Identify appropriate patients based on both pathological and clinical characteristics to ensure timely and optimal management of patients with early symptomatic AD

Financial Support

Supported through an independent educational grant from Lilly.

Target Audience

Physicians, physician associates (PAs), and nurse practitioners (NPs) specializing in dementia, psychiatry, neurology, or geriatrics

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note to Physician Associates: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™  from organizations accredited by the Accreditation Council for Continuing Medical Education.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

UEMS-EACCME®

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Disclosure Declaration

Dr. Atri reports the following financial relationships:

Advisory Board: Eisai Inc.; Lundbeck; Merck & Co., Inc.; Novo Nordisk; and Roche/Genentech, Inc.

Consultant: Eisai Inc.; Lundbeck; Merck; Novo Nordisk; Prothena; and Roche/Genentech, Inc.

Grants: (Institutional research grant/contract funding): Arizona Department of Health Services; Foundation for National Institutes of Health (FNIH); Gates Ventures; National Institute on Aging (NIA/NIH; and Washington University St Louis (as Project Arm Leader for DIAN-TU)

Research Support (Institutional research support or grants for observational or biomarker studies or clinical trials): Alzheimer’s Disease Consortia – Coordinating research institutes or government funding (Alzheimer’s Clinical Trials Consortium (ACTC); Alzheimer’s Disease Cooperative Study (ADCS); Alzheimer’s Therapeutic Research Institute; (ATRI); National Institutes of Health (NIH); Athira Pharma, Inc.;  Alzheon, Inc.; Biohaven (with ADCS); Eisai Inc. (with ATRI/ACTC); Global Alzheimer’s Platform Foundation; Indiana University (observational cohort); Johns Hopkins (clinical trial); Lilly (with ACTC/NIH); PEACE-AD Study (with ADCS); Vivoryon (with ADCS)

Dr. Zetterberg reports the following financial relationships:

Advisory Board/Consultant: AbbVie Inc.; Acumen Pharmaceuticals, Inc.; Alector, Inc.; Alzinova; ALZPath Inc.; Annexon Biosciences; Apellis Pharmaceuticals; Artery Therapeutics, Inc.; AZTherapies, Inc.; Cognito Therapeutics; Cognition Therapeutics; Denali Therapeutics; Eisai Europe Ltd; Merry Life; NervGen Pharma Corp.; Novo Nordisk; OptoCeutics; Passage Bio; Pinteon Therapeutics; Prothena; Red Abbey; reMYND; Roche; Samumed; Siemens Healthineers; Triplet Therapeutics, Inc.; and Wave Life Sciences

Speakers Bureau: AlzeCure Pharma; Biogen; Cellectricon; Fujirebio; Lilly; Novo Nordisk; and Roche

Stock Shareholder (ownership interest): Co-founder and stock shareholder of Brain Biomarker Solutions in Gotheburg AB (BBS), which is a part of the GU Ventures Incubator Program

The following individuals have no financial relationships to disclose: 

Thomas Heinrich, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Evan Luberger (Planning Committee)
Kellie Busby, PharmD, BCPP (Planning Committee)
Erin Spencer (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-231-040124-11

Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer’s Disease
Event Date: 04/01/2024 at 5:00 am EST
Begin

Activities in the Series

Alzheimer’s Disease
03/01/2024 at 5:00 am EST

Deciphering Patient Selection Related to Current and Emerging Amyloid-Targeting Therapies (ATTs)

0.5
Begin Learn More
Alzheimer’s Disease
02/29/2024 at 5:00 am EST

Untangling the Data: pTau and Neurofibrillary Tangles as Part of Early Alzheimer’s Detection

0.5
Begin Learn More